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Pathological angiogenesis is a hallmark of cancer 
and various inflammatory conditions including 
ocular neovascular diseases (1, 2). Recent studies 
have led to the discovery of a growing number 
of antiangiogenic molecules, some of which are 
already being evaluated in clinical trials (1, 2). 
The most established approach for limiting path­
ological  angiogenesis  involves  blockade  of   
the vascular endothelial growth factor (VEGF) 
pathway (3–5); however, several studies have 
shown that VEGF blockade damages healthy 
vessels and results in toxic side effects (6, 7) and 
that interrupting the VEGF blockade induces 
rapid vascular regrowth in tumors (8). Clinical 
trials involving patients with neovascular age­
related macular degeneration have shown that 
VEGF blockade has limited effectiveness in some 
patients (5). Therefore, several groups have ex­
plored other targets that could potentially be 
combined with VEGF blockade (9–11). In par­
ticular, tumor­associated hematopoietic cells are 
thought to be a promising therapeutic target, es­
pecially neutralizing Bv8, which promotes both 
tissue­specific  angiogenesis  and  hematopoietic 
cell mobilization (10).
Macrophage CSF (M­CSF) (12) is a cytokine 
required for the differentiation of monocyte lin­
eage cells (e.g., tissue macrophages, osteoclasts, 
and microglia) during development (13, 14). Al­
though greatly reduced numbers of monocyte 
lineage cells are present in osteopetrotic (op/op) 
mutant mice (i.e., mice that possess a mutant   
csf-1 gene encoding M­CSF) (13), the potential 
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Antiangiogenic therapy for the treatment of cancer and other neovascular diseases is desired 
to be selective for pathological angiogenesis and lymphangiogenesis. Macrophage colony-
stimulating factor (M-CSF), a cytokine required for the differentiation of monocyte lineage 
cells, promotes the formation of high-density vessel networks in tumors and therefore pos-
sesses therapeutic potential as an M-CSF inhibitor. However, the physiological role of M-CSF 
in vascular and lymphatic development, as well as the precise mechanisms underlying the 
antiangiogenic effects of M-CSF inhibition, remains unclear. Moreover, therapeutic potential 
of M-CSF inhibition in other neovascular diseases has not yet been evaluated. We used 
osteopetrotic (op/op) mice to demonstrate that M-CSF deficiency reduces the abundance of 
LYVE-1+ and LYVE1 macrophages, resulting in defects in vascular and lymphatic develop-
ment. In ischemic retinopathy, M-CSF was required for pathological neovascularization but 
was not required for the recovery of normal vasculature. In mouse osteosarcoma, M-CSF 
inhibition effectively suppressed tumor angiogenesis and lymphangiogenesis, and it disorga-
nized extracellular matrices. In contrast to VEGF blockade, interruption of M-CSF inhibition 
did not promote rapid vascular regrowth. Continuous M-CSF inhibition did not affect healthy 
vascular and lymphatic systems outside tumors. These results suggest that M-CSF–targeted 
therapy is an ideal strategy for treating ocular neovascular diseases and cancer.
© 2009 Kubota et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.jem.org/misc/terms.shtml). After six months   
it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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MMP­2 (not depicted) expression was detected on the cell 
surfaces  of  macrophages.  Both  of  these  MMPs  are  macro­
phage­derived proteases that work with modulating extracel­
lular matrix (ECM) proteins, such as fibronectin, to remodel 
vascular  structures  (24).  Macrophages  contribute  to  pro­
grammed cell death in temporary hyaloid vessels via Wnt7b 
(25); however, their role in the formation of retinal vascular 
plexus has not yet been clarified. Therefore, we examined the 
role of M­CSF in developmental angiogenesis by examining 
the retinal vascular structures of op/op mice, which lack mac­
rophages stained with Mac­1, F4/80, CD45, or isolectin (Fig. 1, 
G and H). By postnatal day (P) 2, branching was reduced in 
the vascular plexus of the op/op retina (Fig. 2, A, B, and K), but 
the numbers of endothelial tip cells and filopodia (which are 
regulated by VEGF [26]) were comparable to those in wild­
type mice (Fig. 2 J). Vascular defects in the op/op retina were 
also detected on P4, as shown by significantly reduced branch­
ing and insufficient arterial­venous patterning (Fig. 2, C, D, 
and K). The reduced branching observed in op/op mice recov­
ered as development progressed (Fig. 2 K and Fig. S1, A and 
B). 3 mo after birth, the vasculature of op/op retinas was com­
parable to that in +/+ retinas (Fig. S1, C and D). We then in­
vestigated the mechanisms underlying vascular impairment in 
the op/op retina. Although VEGF expression remained the 
same (Fig. 2, E and F), the expression of MMP­2 and MMP­9 
(Fig. 2 I) was decreased in the op/op retina. Presumably because 
of this decreased proteinase activity, op/op retina showed disor­
dered fibronectin architecture (Fig. 2, G and H). To examine 
the function of M­CSF in the postnatal developing retina, 
wild­type mice were systemically treated with a small molecule 
tyrosine kinase inhibitor specific for c­fms (Ki20227) (27) or 
intraocularly injected with anti–c­fms neutralizing antibodies 
(AFS98) (28) during the postnatal stage. Both treatments sig­
nificantly reduced branching by P4, but the number of endo­
thelial tip cells was comparable to that in control mice (i.e., 
mice treated with vehicle alone) (Fig. 2, L–P). The reduction 
rate for branching points was greater in response to M­CSF 
inhibition than in response to M­CSF deficiency, suggesting 
that some form of compensation occurs in the postnatal op/op 
retina. When retinas were treated with Ki20227/anti–c­fms 
antibodies, macrophages decreased in number and exhibited 
insufficient stellate morphology (Fig. 2, L–P). Thus, these re­
sults suggest that M­CSF contributes to developmental vascu­
lar remodeling independently of VEGF but does not contribute 
to the maintenance of adult vasculature.
M-CSF is required for pathological neovascularization  
but not for recovery of normal vasculature in oxygen-
induced retinopathy (OIR)
Although normalized vasculature in the later stage of op/op 
mice suggests that M­CSF is not required for the maintenance 
of stable adult vasculature, we suspected that M­CSF might be 
critical for the induction of pathological neovascularization. 
The OIR model (29) is a widely used system to examine ocu­
lar neovascularization, a condition which resembles prolifera­
tive diabetic retinopathy in humans (30). In this model, the 
effects on angiogenesis and lymphangiogenesis have not been 
evaluated. Recent studies suggest that M­CSF plays a key role 
in the formation of high­density vessel networks and acts as an 
“angiogenic switch” in a mouse model of mammary tumors 
(15, 16). The inhibition of M­CSF by antisense oligonucle­
otides, small interfering RNAs, or blocking antibodies sup­
presses the growth of human mammary tumor xenografts in 
mice (17, 18). Clodronate liposome, a reagent for depleting 
macrophages, also inhibits tumor growth (19). However, the 
mechanisms underlying the role of M­CSF in tumor progres­
sion, particularly with regards to tumor lymphangiogenesis and 
tumor selectivity, have not been fully dissected.
Osteosarcoma, the most common primary bone tumor,   
is defined as a malignant tumor derived from mesenchymal   
or stromal cells with highly metastatic capacities, particularly in 
the lung and liver (20). Multimodal treatment, often consisting 
of aggressive chemotherapy combined with radical surgical 
resection (e.g., limb amputation), has traditionally been the 
mainstay of osteosarcoma management; however, the progno­
sis of osteosarcoma patients has not improved significantly in 
recent years (20). Lack of an appropriate animal model for hu­
man osteosarcoma has hampered the development of an effec­
tive antiosteosarcoma therapy.
In this study, we used op/op mice to demonstrate that   
M­CSF contributes to both vascular and lymphatic develop­
ment. Furthermore, our data show that M­CSF is required 
for  retinal  pathological  neovascularization  but  not  for  the 
maintenance of stable adult vasculature or lymphatics. Using 
a newly established mouse model of osteosarcoma, we show 
that M­CSF inhibition selectively suppresses tumor angio­
genesis and lymphangiogenesis. In contrast to VEGF block­
ade, the interruption of M­CSF inhibition does not promote 
rapid tumor regrowth. These findings indicate that M­CSF–
targeted therapy is an ideal strategy for the treatment of ocular 
neovascular diseases and cancer.
RESULTS
M-CSF contributes to developmental vascular remodeling 
but not to maintenance of adult vasculature
Postnatal retinal vascular development, a widely used model 
for studying sprouting angiogenesis, can be used to study path­
ological angiogenesis (e.g., the formation of blood vessels in 
tumors) (21, 22). We first characterized macrophages in a retinal 
angiogenesis model. Macrophages stained with Mac­1 were 
found in avascular and vascularized areas and were readily dis­
tinguished from desmin­stained pericytes (Fig. 1 A). Active 
vascular remodeling takes place in capillary areas during the 
pruning of vascular capillary components (23). Macrophages in 
these areas had large expanded cytoplasms and contained vesi­
cles positive for PECAM­1 (Fig. 1 B) in contrast to the lean 
bodies observed in arterial areas (Fig. 1 C). Immunostaining of 
laminin revealed the presence of basal lamina between macro­
phages and pericytes (Fig. 1 D). We then examined several 
angiogenic factors and were unable to detect VEGF in macro­
phages via in situ hybridization (ISH; Fig. 1 E). Furthermore, 
abundant matrix metalloproteinase (MMP) 9 (Fig. 1 F) and JEM VOL. 206, May 11, 2009 
ARTICLE
1091
or intraocularly injected with anti–c­fms neutralizing anti­
bodies during neovascularization. Both avascular and NVT areas 
dramatically decreased in response to these treatments, relative 
to mice treated with vehicle or control IgG (Fig. 3, J–O and V). 
The number of macrophages surrounding NVT areas dramati­
cally decreased in mice treated with Ki20227/anti–c­fms anti­
bodies, as well as in op/op mice (Fig. 3, R–U [quantification 
not depicted]). Retinas in MMP­9/ mice exhibited signifi­
cantly fewer NVTs but increased physiological revasculariza­
tion (unpublished data). In contrast, treatment with SU1498,   
a potent and selective inhibitor of VEGFR2, nonselectively 
suppressed both pathological and physiological angiogenesis 
(Fig. 3, P, Q, and V). Collectively, these data suggest that tar­
geting macrophage/ECM­related molecules selectively inhibits 
pathological neovascularization but does not affect the recov­
ery of normal vasculature in the OIR model.
M-CSF contributes to postnatal lymphatic development
Macrophages are thought to play important roles in lymphan­
giogenesis, particularly in macrophage subpopulations that ex­
press LYVE­1, a marker of lymphatics. In these subpopulations, 
central area of established vasculature is obliterated by hyperoxic 
insult, creating an ischemic area. After mice are returned to 
room air, revascularization occurs and the normal vasculature is 
recovered, although some vessels (i.e., neovascular tufts [NVTs]) 
proliferate abnormally toward the vitreous body (Fig. 3 A). 
Increased expression of csf-1, vegf-a, and the c­fms receptor 
(csfr-1) was observed during neovascularization in the OIR 
model (Fig. 3, B–D). In addition, csfr-1 expression was higher 
in FACS­sorted Mac1+ cells than in Mac1 cells (Fig. 3 E), 
suggesting that csfr-1 is specific to macrophages. These data also 
indicate that csfr-1 expression in tissues largely reflects the num­
ber of macrophages. There was no significant difference in the 
vaso­obliterated areas of wild­type and op/op retina on P11 in 
the OIR model (Fig. S2, A, B, E, F, and I), suggesting that 
vascular resistance to hyper oxygen insult was not altered in 
op/op retina. Similarly, Ki20227 treatment did not alter vascular 
resistance to hyper oxygen insult (Fig. S2, C, D, G, H, and J). 
On P16, the op/op retina exhibited a dramatic decrease in 
NVTs but an increase in physiological revascularization (Fig. 3, 
F–I and V). To confirm the role of M­CSF in neovasculariza­
tion, wild­type mice were systemically treated with Ki20227 
Figure 1.  Characterization of macrophages in the developing retina. (A–C) Triple immunohistochemistry (IHC) of Mac-1 (green), desmin (red), and 
PECAM-1 (blue) within the P4 retina (representative images of three independent experiments). Macrophages in the venous/capillary (v) area possessed 
largely expanded cytoplasms and contained vesicles positive for PECAM-1 (B) in contrast to their lean bodies in the arterial area (a; C). (D) Triple IHC of 
Mac-1 (green), desmin (red), and laminin (blue; a representative image of three independent experiments). Macrophages (closed arrowheads) were identi-
fied in the perivascular space outside the basement membrane, whereas pericytes (arrows) and circulating monocytes (open arrowheads) were identified 
inside the basement membrane. (E) An ISH analysis of VEGF (purple) combined with isolectin B4 staining (green) of P4 (a representative image of six  
independent experiments). Macrophages (arrowheads) did not express VEGF, whereas astrocytes abundantly expressed VEGF. (F) An IHC analysis of MMP-9 
(red) combined with isolectin B4 staining (blue; representative images of three independent experiments). MMP-9 was abundantly expressed in macro-
phages (arrowheads). (G) Double IHC of isolectin B4 (blue) and Mac-1, CD45, or F4/80 (green, as indicated) at P4 (representative images of eight indepen-
dent experiments). Note that perivascular cells stained with Mac-1, CD45, F4/80, or isolectin were all identical and were absent from op/op mice.  
(H) Quantification of perivascular cells (mean ± SD) stained with Mac-1, CD45, or F4/80 (n = 8). Bars, 50 µm.1092 M-CSF INHIBITION SELECTIVELY TARGETS TUMORS | Kubota et al.
Figure 2.  M-CSF contributes to developmental vascular remodeling. (A–D) An IHC analysis of PECAM-1 in P2 (A and B) and P4 (C and D) retinas 
(representative images of seven independent experiments). Note the reduced branching at P2 (indicated by arrowheads in B) and insufficient arterio-venous 
(a and v, respectively) patterning at P4 in op/op mice. (E and F) An ISH analysis of VEGF (purple) combined with isolectin B4 staining (green) at P4 (represen-
tative images of three independent experiments). VEGF expression (asterisks) was not altered in op/op mice. Also note the insufficient arterio-venous (a and 
v, respectively) patterning in op/op mice. (G and H) Double IHC of PECAM-1 (blue) and fibronectin (green) at P4 (representative images of four independent 
experiments). Note the irregular fibronectin proteins excessively deposited around the endothelial tubes (arrowheads) and rounded debris in the parenchy-
mal area (arrows) in op/op mice. (I) Western blots of MMP-2 and MMP-9 in the P4 retina. Expression of MMP-2 and -9 decreased in the op/op mice. Repre-
sentative panels are shown from three independent experiments. (J) The number of tip cells and filopodia (mean ± SD) were quantified as shown on the  
left (n = 7). (K) Quantification (mean ± SD) of branching points (n = 7). (L–O) Double IHC of Mac-1 (green) and PECAM-1 (blue) in P4 retinas after systemic 
treatment with vehicle (L) or Ki20227 (M) during P1–P4 or after intraocular injection with control IgG (N) or anti–c-fms IgG (O) at P1 (representative images 
of seven independent experiments). Note reduced branching points (yellow dots) and unaffected tip cells (red dots) in Ki20227-treated and anti–c-fms  
IgG-treated mice. Macrophages in retinas treated with Ki20227 and anti–c-fms antibodies exhibited insufficient stellate morphology and were present  
in lower numbers. (P) Quantification (mean ± SD) of Mac-1+ perivascular cells, tip cells, or branching points (n = 7). Bars, 50 µm. *, P < 0.05; **, P < 0.01.JEM VOL. 206, May 11, 2009 
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Figure 3.  M-CSF is required for pathological neovascularization but not for the recovery of normal vasculature in OIR. (A) Isolectin staining  
of retinas in an OIR model. The central area of established vasculature was obliterated by hyperoxic insult, resulting in an avascular area (asterisks). After 
returning the mice to room air, normal vasculature was recovered via revascularization (arrows), although NVTs proliferated toward the vitreous body.  
(B–D) Relative expression (mean ± SD) of vegf-a (B), csfr-1 (C), or csf-1 (D) in retinal tissues exposed to normoxic conditions or in an OIR model (n = 5; all 
experiments were performed in quadruplicate and the mean for each sample was obtained). (E) Relative expression (mean ± SD) of csfr-1 in FACS-sorted  
Mac-1+ or Mac-1 cells obtained from P16 retinas in an OIR model (n = 5). (F–Q) Isolectin staining of P16 retinas in an OIR model (representative images 
of six independent experiments). Note the decreased avascular area (yellow) and NVT area (red) in op/op mice (H and I) and mice systemically treated with 
Ki20227 (L and M) during P12 and P16 or in mice that were given intraocular anti–c-fms antibodies during P12 (N and O). Systemic treatment with  
SU1498 decreased NVT area and increased avascular area (P and Q). (R–U) Double IHC of Mac-1 (green) and isolectin (blue) in the P16 retinas of an OIR 
model. Macrophages in op/op retinas or retinas treated with Ki20227/anti–c-fms antibodies were reduced in number and exhibited insufficient stellate  
morphology. (V) Quantification (mean ± SD) of the avascular area or NVT area (n = 6). Bars, 200 µm. *, P < 0.05; **, P < 0.01.1094 M-CSF INHIBITION SELECTIVELY TARGETS TUMORS | Kubota et al.
Figure 4.  M-CSF contributes to postnatal lymphatic development. (A–C) Triple IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in tracheas 
(representative images of four independent experiments). Note the LYVE-1+ macrophages in the vascularized area (arrows). (D) FACS analysis of dissociated JEM VOL. 206, May 11, 2009 
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with AX cells and were accompanied by intratumor high­
density vascularization and abundant peritumoral lymphatics 
(Fig. 5, A–E). To analyze the effects of M­CSF inhibition, 
Ki20227  or  anti–c­fms  antibodies  were  administered  via   
daily subcutaneous injections. Mice treated with Ki20227 or   
anti–c­fms antibodies exhibited suppressed tumor growth, 
dramatically decreased tumor vascularization and peritumoral 
lymphatics (Fig. 5, A–G and Q–T), and decreased BrdU   
incorporation by tumor cells relative to control mice (Fig. 5, 
H–J, U, and V). Although small calcified loci were detected 
at the center of tumors in vehicle­treated mice, early and 
massive calcified loci were detected throughout the trans­
planted tumors in mice treated with Ki20227 or anti–c­fms 
antibodies (Fig. 5, K–M). Mice treated with Ki20227 or anti–
c­fms antibodies exhibited dramatically decreased peritu­
moral LYVE­1+ macrophages and perivascular macrophages 
infiltrated into tumors compared with control mice (Fig. 5, 
N–P). In contrast to VEGFR2 neutralization (11), continu­
ous treatment of adult mice with Ki20227 or anti–c­fms   
antibodies for a period of 56 d did not affect healthy vascular 
and lymphatic systems outside the tumor (Fig. 5 W). Collec­
tively, M­CSF inhibition selectively suppressed tumor angio­
genesis and lymphangiogenesis.
We performed in vitro culture experiments to determine 
if the tumor­suppressing effects of c­fms inhibition are medi­
ated by effects on tumors or on recruited monocytes. Hypoxic 
growth  resulted  in  osteogenic  differentiation  and  M­CSF   
expression and decreased proliferation in cultured AX cells 
(Fig. S4, A–C). However, supplementation with 100 nM 
Ki20227, a sufficient dose for the inhibition of c­fms kinase 
(27), did not affect osteogenic differentiation or proliferation 
in AX cells (Fig. S4, A and F). Supplementation with 100 nM 
Ki20227 inhibited survival and proliferation in cultured BM 
mononuclear cells (MNCs; unpublished data). To identify the 
potential ligand–receptor interactions resulting from M­CSF 
signaling between tumors and macrophages, we compared the 
expression of M­CSF and c­fms in cultured AX cells and in 
BM MNCs. Cultured AX cells exhibited high levels of csf-1 
expression, compared with cultured MNCs (Fig. S4 D), but 
relatively lower levels of csfr-1 (Fig. S4 E) expression. These   
in vitro data suggest that the tumor­suppressing effects of   
M­CSF inhibition are mediated by effects on recruited mac­
rophages but do not directly affect AX cells.
the number of LYVE1+ macrophages correlate with the extent 
of tissue lymphangiogenesis (31). In the developing trachea, 
the emergence of LYVE­1 macrophages preceded that of 
LYVE­1+ macrophages, and most LYVE­1+ macrophages 
were present in vascularized areas (Fig. 4, A–C). Furthermore, 
c­fms expression was more abundant in LYVE­1+ than in 
LYVE­1 macrophages (Fig. 4 D). As it is likely that M­CSF/
c­fms signaling contributes to lymphangiogenesis, we exam­
ined developing lymphatic structures in op/op mice. At P15, 
the number of LYVE­1 and LYVE­1+ macrophages dramat­
ically decreased in the tracheas and ears of op/op mice, and   
reduced lymphatic branching was observed (Fig. 4, E–H, O, 
and P). Furthermore, tissue fluids drained more slowly in the 
limbs and ears of op/op mice (Fig. 4, I–L). By P15, some op/op 
mice exhibited apparent perforation of the dorsal tracheal sur­
face (Fig. 4, E and F, insets), presumably as a result of abnor­
mal lymphatic drainage. Although hydrocephalus is thought 
to underlie the high lethality of op/op mice at this stage (14), 
tracheal perforation could also lead to death. However, op/op 
mice that survived for 3 mo possessed normal lymphatic sys­
tems (unpublished data). The op/op mice exhibited normal 
embryonic lymphangiogenesis but lacked LYVE­1+ macro­
phages (Fig. 4, M and N; and Fig. S3). Treatment with Ki20227 
or anti–c­fms antibodies decreased both LYVE­1 and LYVE­
1+ macrophages and reduced the extent of lymphatic branch­
ing (Fig. 4, R and S). Collectively, these data show that M­CSF 
contributes to the appearance of LYVE­1+ macrophages and 
postnatal lymphatic development.
M-CSF inhibition selectively suppresses tumor angiogenesis 
and lymphangiogenesis
The mechanisms underlying developmental angiogenesis   
and lymphangiogenesis may impact tumor angiogenesis and 
lymphangiogenesis (1, 2, 32); thus, we hypothesized that   
M­CSF–targeted therapies selectively suppress tumor angio­
genesis and lymphangiogenesis. These effects may be espe­
cially noticeable in osteosarcomas, which express high levels 
of M­CSF (33). Therefore, we analyzed a mouse model of 
osteosarcoma, in which mice were transplanted with a newly 
established osteosarcoma cell line, AX (unpublished data). 
This line was established from c­Myc–overexpressing Ink4a/
ARF/ BM­derived stromal cells transfected with EGFP. 
Tumors grew actively in mice subcutaneously inoculated 
cells (a representative plot of three independent experiments). Note the more abundant expression of c-fms in LYVE-1+ than in LYVE-1 macrophages.  
(E–H) Whole-mount IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in P15 tracheas (E and F) or ears (G and H; representative images of six  
independent experiments). Note the reduced lymphatic branching in op/op mice. Insets in E and F indicate bright field views of P15 trachea. Note the 
perforation typically seen in op/op mice (arrowhead). (I–L) Lymphangiography in ears (I and K) and limbs (J and L; representative images of three  
independent experiments). Note that the blue dye (arrowheads) observed in the lymphatic ducts of wild-type mice is not seen in op/op mice.  
(M and N) Whole-mount IHC of LYVE-1 in the hearts of E17 embryos (representative images of three independent experiments). The op/op mice exhibited 
normal lymphangiogenesis, although they lacked LYVE-1+ macrophages. (O–Q) Quantification (mean ± SD) of LYVE-1+ macrophages or lymphatic branch-
ing points (n = 6 [O and P]; n = 3 [Q]). (R) Triple IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in P15 tracheas or ears systemically treated with  
vehicle (methylcellulose), Ki20227, control IgG, or anti–c-fms IgG during P8 and P15. Treatment with Ki20227 or anti–c-fms IgG decreased LYVE-1  
and LYVE-1+ macrophages and reduced lymphatic branching (representative images of six independent experiments). (S) Quantification (mean ± SD)  
of LYVE-1+ macrophages or lymphatic branching points (n = 6). Bars: (I–N) 200 µm; (A–C, E–H, and R) 50 µm. *, P < 0.05; **, P < 0.01.
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Figure 5.  M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis in mouse osteosarcoma. (A and B) Typical ap-
pearance of mice 42 d after transplantation with AX cells. Arrows indicate tumor areas. (C and D) Quantification (mean ± SD) of tumor diameter (n = 5). 
(E–G) An IHC analysis of PECAM-1 (green) and LYVE-1 (red) in tumors 21 d after transplantation (representative images of seven independent experi-
ments). Arrowheads in E indicate peritumoral lymphatics. Treatment with Ki20227 or anti–c-fms IgG decreased the amount of associated vascularization 
and peritumoral lymphatics. (H–M) An IHC analysis using GFP (green) and BrdU (red; H–J) or Alizarin red staining (K–M; representative images of five 
independent experiments). Treatment with Ki20227 or anti–c-fms IgG decreased BrdU incorporation into tumor cells but increased tumor calcification 
(asterisks). (N–P) An IHC analysis of Mac-1 (green), PECAM-1 (blue), and LYVE-1 (red) in tumors 21 d after transplantation. Dotted lines indicate tumor JEM VOL. 206, May 11, 2009 
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we compared the antitumor effects of M­CSF inhibition and 
VEGF inhibition in three differential therapeutic protocols, 
including the protocol that involved interruption of administra­
tion in addition to vehicle or continuous treatment (Fig. 7 Q). 
Although continuous SU1498 administration greatly inhib­
ited tumor growth and vascular/lymphatic growth in tumors, 
as did Ki20227 administration, interruption of SU1498 treat­
ment resulted in rapid vascular and lymphatic regrowth (Fig. 7, 
S–U).  In  contrast,  interruption  of  Ki20227  administration 
greatly reduced vascular and lymphatic growth (Fig. 7, V–X). 
Although the interruption of SU1498 treatment did not suffi­
ciently inhibit tumor metastasis and cancer death, sustained 
effectiveness was observed after the interruption of Ki20227 
administration (Fig. 7, Y, Z, and AA).
DISCUSSION
We used op/op mice to demonstrate that M­CSF–dependent 
macrophages contribute to both vascular and lymphatic devel­
opment. Furthermore, we show that M­CSF is required for 
pathological neovascularization but not for the recovery of 
normal vasculature in OIR. Deficiency in M­CSF does not 
affect the maintenance of stable adult vasculature and lymphat­
ics. In mice with osteosarcoma, M­CSF inhibition selectively 
suppressed tumor angiogenesis and lymphangiogenesis and de­
creased tumor regrowth after the interruption of treatment.
Our data showing the highly specific effects of M­CSF 
inhibition on pathological angiogenesis and lymphangiogen­
esis are supported by the observation that no detectable abnor­
malities in adult vascular and lymphatic systems were found 
in op/op mice. In contrast to the effects of VEGF blockade, 
interruption of M­CSF inhibition did not promote rapid   
tumor regrowth but rather improved the prognosis relative 
to treatment with a vehicle. This difference might be a result 
of the effects of M­CSF inhibition on the “sleeves” of the 
basement membrane. These so­called sleeves are conserved 
during VEGF blockade and assist with rapid vascular regrowth 
in primary tumors (8). The physiological role of retinal mac­
rophages in developmental vascular remodeling, but not in 
angiogenic sprouting, suggests that M­CSF inhibition and 
VEGF blockade target different factors. Indeed, the tumor­
suppressive effects of M­CSF inhibition are independent 
of VEGF signaling. Furthermore, a recent study showed that 
tumor refractoriness to anti­VEGF treatment is mediated by 
Mac­1+Gr1+ myeloid cells (37), suggesting that M­CSF–
targeted therapy may serve as a useful secondary therapy in 
patients who are resistant to VEGF blockade.
We showed that retinal macrophages express high levels of 
MMP­2 and MMP­9 but not VEGF. These expression patterns 
M-CSF inhibition suppresses tumor metastasis of mouse 
osteosarcoma and improves prognosis
We then examined the effects of Ki20227 and anti–c­fms an­
tibodies on tumor metastasis and disease prognosis. We per­
formed a functional analysis of tumor­associated lymphatics 
by examining the dye efflux capacity of transplanted tumors. 
Tumors in mice treated with Ki20227 or anti–c­fms antibod­
ies exhibited significantly higher levels of dye retention com­
pared with tumors in vehicle­treated mice (Fig. 6, A–C and 
V). In vehicle­treated mice, transplanted AX cells spread to 
the liver and lung (Fig. 6, D, G, J, M, P, and S), two major 
metastatic sites in human osteosarcoma (20). Approximately 
20% of mice remained alive 56 d after tumor cell inoculation 
(Fig. 6 X). However, metastases were dramatically suppressed 
in mice treated with Ki20227 or anti–c­fms antibodies (Fig. 6, 
D–U and W), and >90% of these mice survived for 56 d 
(Fig. 6 X). Aside from its role in M­CSF/c­fms signaling, 
VEGF/Flt1 plays a profound role in the recruitment of mac­
rophages and the progression of cancer in various models   
(11, 34–36). To examine the involvement of VEGF/Flt1 sig­
naling in our established mouse osteosarcoma, AX cells were 
transplanted into mice deficient in Flt1 tyrosine kinase (Vegfr1 
tk/). Deficiency in Flt1 tyrosine kinase did not affect the 
number of recruited macrophages (Fig. S5, A and B), tumor 
growth (Fig. S5 C), or metastasis (Fig. S5, D–G), suggesting 
that macrophages are less dependent on VEGF/Flt1 signaling 
in this model than in other cancer models.
M-CSF inhibition disorganizes extracellular matrices  
and suppresses tumor progression when treatment  
is interrupted
To explore the differences between M­CSF inhibition and 
VEGF inhibition, we compared the antitumor effects of two 
small tyrosine kinase inhibitors, Ki20227 and SU1498. Vascular 
ECM structures stained by fibronectin (which has the poten­
tial to induce tumor vascular regrowth) (8) retained the spatial 
distribution surrounding endothelial cells treated with SU1498 
or a vehicle (Fig. 7, A–F). In contrast, these structures were 
irregularly deposited throughout the tumors in Ki20227­
treated mice (Fig. 7, G–L), suggesting a disturbance in the   
remodeling or degradation of ECM scaffolds. In contrast to 
Ki20227,  SU1498  did  not  affect  tumor­associated  macro­
phages (Fig. 7, M and N). Tumors transplanted into MMP­9/ 
mice exhibited irregularly deposited ECM structures, which is 
similar to tumors transplanted into Ki20227­treated mice (Fig. 
7, O and P), and exhibited decreased tumor growth (not de­
picted). These data suggest that the proteases produced by 
macrophages contribute to matrix remodeling. Furthermore, 
margins. Treatment with Ki20227 or anti–c-fms IgG decreased the peritumoral LYVE-1+ macrophages (arrowheads) and perivascular macrophages (aster-
isks) into tumors (representative images of seven independent experiments). (Q–T) Quantification (mean ± SD) of vascularized areas (Q and R) or periph-
eral areas with lymphatics (S and T; n = 7). (U and V) Quantification (mean ± SD) of BrdU+GFP+ cells (n = 5). (W) An IHC analysis using the indicated 
antibodies for adult retina, trachea, or ears after 56 d of treatment (representative images of four independent experiments). No vascular and lymphatic 
abnormalities were observed in mice treated with Ki20227 or anti–c-fms IgG, although these treatments decreased LYVE-1 and LYVE-1+ macrophages. 
Bars: (W) 200 µm; (E–P) 50 µm. *, P < 0.05; **, P < 0.01.
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Figure 6.  M-CSF inhibition suppresses tumor metastasis of mouse osteosarcoma and improves prognosis. (A–C) Representative appearance of  
tumors 2 h after injection with Evans blue dye (representative images of five independent experiments). (D–U) Fluorescent views (D–F and M–O), IHC for  
GFP (green) and TOTO3 (blue; G–I and P–R), or hematoxylin and eosin staining (J–L and S–U) in the liver or lung 56 d after tumor inoculation (repre-
sentative images of five independent experiments). Note that the multiple metastatic masses (arrowheads) in control mice were completely absent in  
mice treated with Ki20227/anti–c-fms IgG. (V–X) Quantification (mean ± SD) of the OD600 measurements of extracted dye (V; n = 5), liver and lung  
metastasis at day 56 (W; n = 5), and survival rate (X; at least six mice were examined in each group). Bars, 200 µm. *, P < 0.05; **, P < 0.01.
are thought to reflect the vascular defects in op/op mice, which 
are characterized by normal sprouting angiogenesis and im­
paired vascular remodeling. Although VEGF plays a critical 
role in angiogenic sprouting (26), MMP­2 and MMP­9 are 
gelatinase proteinases with overlapping substrates (e.g., fibro­
nectin) that function together in some situations such as aortic 
aneurysms (24). One of the major questions in our study   
is whether disordered fibronectin architecture, which is pre­
sumably caused by the absence of macrophage MMP­2 and 
MMP­9, is the primary cause of vascular defects in op/op mice. 
However, the precise function of specific proteinases is gener­
ally difficult to discern because of the considerable redundancy 
of these enzymes (24). In fact, MMP­9/ mice exhibit normal 
vascular  development  and  normal  ECM  structures  in  their   
developing retina (unpublished data), which is in contrast to 
the dramatically decreased NVTs observed in the OIR model. 
Clinical observations of diabetic microvessels in humans have 
revealed that disordered fibronectin structures are the earliest 
events preceding various capillary defects (38). These observa­
tions also support the idea that disordered fibronectin architec­
ture  accounts  for  defects  associated  with  impaired  vascular 
remodeling in the op/op retina.
Previous studies have shown that M­CSF/c­fms signaling 
promotes the differentiation of circulating monocytes into JEM VOL. 206, May 11, 2009 
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Figure 7.  M-CSF inhibition disorganizes extracellular matrices and suppresses tumor progression when treatment is interrupted. (A–L) An  
IHC analysis of PECAM-1 (green) and fibronectin (red) in tumors 21 d after transplantation (representative images of three independent experiments). 
Note that massively deposited fibronectin proteins were distributed throughout the tumors (asterisks) in Ki20227-treated mice but not in SU1498-treated 
mice, whereas tumor vasculature decreased in both mice. (M and N) An IHC analysis of Mac-1 (green), PECAM-1 (blue), and LYVE-1 (red) in tumors 21 d 
after transplantation (representative images of three independent experiments). Dotted lines indicate tumor margins. Treatment with SU1498 did not 
affect LYVE-1 or LYVE-1+ macrophages. (O and P) Fibronectin staining of tumors 21 d after transplantation into MMP-9+/+ or MMP-9/ mice (represen-
tative images of three independent experiments). Note the presence of massively deposited fibronectin proteins (asterisk) in the MMP-9/ mice.  
(Q) A modified scheme involving the administration of small molecule inhibitors. Administration was either continuous for 56 d (continuous) or termi-
nated at day 21 (interrupt) after tumor inoculation. (R) Quantification (mean ± SD) of tumor diameter (more than five mice were examined in each  
regimen). (S–X) An IHC analysis of PECAM-1 (green) and LYVE-1 (red) in tumors 21 d after transplantation (representative images of three independent 
experiments). Although continuous SU1498 administration greatly inhibited vascular and lymphatic growth, interruption of treatment resulted in rapid 
vascular (asterisk) and lymphatic (arrows) regrowth. In contrast, Ki20227 reduced vasculature and lymphatics even after the interruption of treatment.  
(Y) Fluorescent views of liver or lung at day 56 in each regimen (representative images of five independent experiments). Although the interruption of 
SU1498 treatment caused multiple tumor metastases (as in vehicle treatment), metastatic masses were greatly reduced when Ki20227 treatment was 
interrupted. (Z) Quantification (mean ± SD) of liver and lung metastases at day 56 in each regimen (n = 5). (AA) Survival rate (more than five mice were  
examined in each regimen). Bars: (Y) 1 mm; (A–P and S–X) 50 µm. *, P < 0.05; **, P < 0.01.1100 M-CSF INHIBITION SELECTIVELY TARGETS TUMORS | Kubota et al.
Mac­1 (M1/7; BD), F4/80 (A3­1; AbD Serotec), PDGFR­ (APA5; eBiosci­
ence), and desmin (Dako). Primary polyclonal antibodies included Alexa Fluor 
488–conjugated anti­GFP (Invitrogen), MMP­9 (Santa Cruz Biotechnology, 
Inc.), collagen IV (Cosmo Bio), LYVE­1 (ReliaTech), and fibronectin (Dako). 
Secondary  antibodies  included  Alexa  Fluor  488  fluorescence­conjugated 
IgGs (Invitrogen) or Cy3/Cy5­conjugated IgGs (Jackson ImmunoResearch 
Laboratories). In preparation for nuclear staining, specimens were treated 
with TOTO3 (Invitrogen) or DAPI (Invitrogen). In some experiments, 
blood  vessels  and  monocyte  lineage  cells  were  simultaneously  visualized   
using biotinylated isolectin B4 (Sigma­Aldrich), followed by treatment with 
fluorescent streptavidin conjugates (Invitrogen).
Tumor inoculation and c-fms inhibitor treatment. The AX cells were 
cultured in DMEM containing 10% FCS, and the medium was changed daily. 
Approximately 2 × 106 cells in subconfluent culture were resuspended in 200 µl 
of medium and were subcutaneously transplanted into the back of mice. The fol­
lowing was injected daily into subcutaneous tissues at the base of the tail: 50 
mg/kg (BW) of Ki20227 (27) dissolved in 200 µl methylcellulose; 50 mg/kg 
(BW) of AFS98, a rat monoclonal anti­murine c­fms antibody (IgG2a; provided 
by S.­I. Nishikawa and S. Nishikawa, Riken Center for Developmental Biology, 
Kobe, Japan) (28), dissolved in 200 µl of PBS; an isotype­matched irrelevant rat 
IgG dissolved in 200 µl of PBS; 9 mg/kg (BW) of SU1498 (EMD) dissolved in 
100 µl of DMSO; or vehicle only. Metastatic lesions were enumerated by count­
ing detectable GFP+ masses under a fluorescent microscope.
Intraocular injections. Injections into the vitreous body were performed 
using 33­gauge needles, as described previously (26, 40). Approximately 1 
mg/ml AFS98 or an isotype­matched irrelevant rat IgG dissolved in 50 nl 
of sterile PBS was injected on P1 or P12 (OIR).
Lymphangiography. Functional lymphatic vessels were visualized by injecting 
20 µl of Evans blue dye (5 mg/ml; Sigma­Aldrich) into the hindlimb footpad or 
the ear, and lymphatic vessels were analyzed via light microscopy. In preparation 
for the tumor dye efflux experiment, we injected 50 µl of Evans blue dye into   
tumors and sacrificed animals 2 h later. Approximately 100 mg of tumors were 
dissected and incubated in 1 ml formamide (to extract the Evans blue dye), and 
the absorbency was measured at OD600 using a spectrophotometer.
Quantitative RT-PCR analysis. Total RNA was prepared from cultured 
cells and reverse transcribed using Superscript II (Invitrogen). Quantitative 
PCR was performed on an ABI 7500 Fast Real­Time PCR system using   
the TaqMan Fast Universal PCR master mix (Applied Biosystems) and a 
TaqMan Gene Expression Assay mixture containing csf-1 (Mm00432688_m1), 
csfr-1 (Mm00432689_m1), or vegf-a (Mm00437304_m1). A mouse ­actin 
(Mm00607939_s1) mixture served as an endogenous control. Data were   
analyzed using 7500 Fast System SDS Software 1.3.1. All experiments were 
performed in quadruplicate and a mean was obtained for each sample.
FACS analysis. Dissected tracheas were incubated at 37°C for 30 min in 
DMEM containing 1% collagenase d (from Clostridium histolyticum; Roche) 
before dissociation by gentle trituration. Harvested cells were immunostained, 
followed by purification and analysis using the FACSVantage (BD).
Confocal microscopy. Fluorescence images were obtained using a confocal   
laser­scanning  microscope  (FV1000;  Olympus).  Scanning  was  performed  in   
sequential laser emission mode to avoid scanning at other wavelengths. Cells or 
substances of interest were quantified in eight (200 µm × 200 µm) fields of view 
per sample in each scanned image, and the mean of eight fields was determined.
Statistical analysis. Results were expressed as means ± SD. The means of 
two groups were compared using a two­tailed Student’s t test. P­values 
<0.05 were considered statistically significant.
Online supplemental material. Fig. S1 shows normal vascular structure 
in op/op mice at P8 and P90. Fig. S2 shows that M­CSF deficiency or M­CSF 
macrophages (13). However, abundant c­fms expression by 
LYVE­1+ macrophages and defective postnatal lymphangio­
genesis in op/op mice suggests that M­CSF also acts on LYVE­
1+ macrophages and lymphangiogenesis. The link between 
the absence of LYVE1+ cells and reduced lymphangiogenesis 
may be explained by reductions in the secretion of VEGF­C, 
VEGF–D, or other inflammatory cytokines by LYVE1+ macro­
phages (11, 31, 32). The significant contribution of BM­derived 
lymphatic endothelial progenitor cells to lymphangiogenesis 
(39) may be responsible for this link.
Other than M­CSF/c­fms signaling, VEGF/Flt1 signaling 
significantly contributes to the recruitment of macrophages 
and tumor progression in various cancer models (11, 34–36). 
In our osteosarcoma model (in which tumor cells expressed 
high levels of M­CSF, just as in human osteosarcoma), de­
ficiency in Flt1 tyrosine kinase did not significantly affect   
tumor progression. These data suggest that tumor progression   
depends primarily on M­CSF/c­fms signaling rather than on 
VEGF/Flt1 signaling. In addition, the Vegfr1 tk/ mice in the 
OIR model did not experience a significant reduction in the 
amount of NVT or in the number of recruited macrophages 
(unpublished data). However, decreases in the number of   
tumor­associated macrophages observed in Vegfr1 tk/ mice 
in other cancer models suggest that VEGF/Flt1 signaling plays 
an important role in the recruitment of macrophages and that 
Flt1­targeted therapy also holds potential as a tumor­selective 
strategy. It would be interesting to determine the extent to 
which M­CSF/c­fms or VEGF/Flt1 signaling affects macro­
phage recruitment in various other cancer models.
Overall, our data show that M­CSF inhibition efficiently 
suppresses pathological angiogenesis and lymphangiogenesis 
in mice with ischemic retinopathy and osteosarcoma. This 
highly selective chemotherapy, which does not affect healthy 
tissues or induce toxic side effects, may be an ideal treatment 
for ocular neovascular diseases and cancer.
MATERIALS AND METHODS
Mice and hyperoxia exposure. The C57BL/6 mice (Japan SLC, Inc.), 
op/op mice (The Jackson Laboratory), MMP­9/ mice (The Jackson Labo­
ratory), and Vegfr1 tk/ mice (34, 35) were used. All animal experiments 
were approved by Keio University and were performed in accordance with 
the Guidelines of Keio University for Animal and Recombinant DNA ex­
periments. The P8 mice and nursing mothers used in the OIR model were 
maintained for 3 d in 85% oxygen and then placed in room air (40). To ex­
amine c­fms inhibition, mice were subcutaneously injected once daily from 
P8 to P11 or from P11 to P16 with 50 mg/kg (body weight [BW]) of 
Ki20227 (27) dissolved in 100 µl methylcellulose or vehicle.
Preparation of whole-mount samples. Isolated eyes, tracheas, and other tis­
sues were fixed for 20 min in 4% paraformaldehyde (PFA) in PBS and dissected 
as previously described (31, 40). Tissues were postfixed and stored in methanol 
at 20°C. The tissue samples were gradually rehydrated for further analysis.
Whole-mount IHC and ISH. IHC analysis of whole­mount samples was 
performed as previously described (31, 40). For whole­mount retinal ISH, 
retinas were briefly digested with proteinase K and hybridized with digoxi­
genin­labeled antisense RNA probes.
Antibodies for IHC. Primary monoclonal antibodies used include hamster 
anti–PECAM­1  (2H8;  Millipore),  rat  anti–PECAM­1  (MEC13.3;  BD), JEM VOL. 206, May 11, 2009 
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inhibition does not affect vaso­obliteration in OIR model. Fig. S3 shows 
that various embryonic tissues in op/op mice exhibit normal lymphangiogen­
esis but lacked LYVE­1+ macrophages. Fig. S4 shows that hypoxia, but not 
Ki20227, induces osteogenic differentiation and decreases proliferation in 
cultured AX cells. Fig. S5 shows that there is no significant difference be­
tween Vegfr1 tk+/+ and Vegfr1 tk/ in tumor progression when transplanted 
with AX cells. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20081605/DC1.
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